公开(公告)号：US07700591B2

公开(公告)日：2010-04-20

申请号：US11129512

申请日：2005-05-13

申请人： Stephen D. Goble ,  Sander G. Mills ,  Lihu Yang ,  Alexander Pasternak ,  Celine Bonnefous ,  Theodore M Kamenecka ,  Jean-Michel Vernier ,  John H. Hutchinson ,  Essa Hu ,  Steven Govek

发明人： Stephen D. Goble ,  Sander G. Mills ,  Lihu Yang ,  Alexander Pasternak ,  Celine Bonnefous ,  Theodore M Kamenecka ,  Jean-Michel Vernier ,  John H. Hutchinson ,  Essa Hu ,  Steven Govek

IPC分类号： A61K31/535 ,  C07D265/12 ,  C07D498/00

CPC分类号： C07D413/08 ,  C07D413/14 ,  C07D417/14

摘要： Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

摘要翻译： 通过使用苯并恶嗪的环氮通过酰胺部分连接到苯并恶嗪基的环戊基化合物，并进一步被杂环部分取代，由式I表示的化合物：其用于调节CCR-2趋化因子受体以预防或治疗炎症 和免疫调节性疾病和疾病，过敏性疾病，特应性病症，包括过敏性鼻炎，皮炎，结膜炎和哮喘，以及自身免疫性病态如类风湿性关节炎和动脉粥样硬化; 和包含这些化合物的药物组合物以及这些化合物和组合物的用途。

公开(公告)号：US20060069088A1

公开(公告)日：2006-03-30

申请号：US11129512

申请日：2005-05-13

申请人： Stephen Goble ,  Sander Mills ,  Lihu Yang ,  Alexander Pasternak ,  Celine Bonnefous ,  Theodore Kamenecka ,  Jean-Michel Vernier ,  John Hutchinson ,  Essa Hu ,  Steven Govek

发明人： Stephen Goble ,  Sander Mills ,  Lihu Yang ,  Alexander Pasternak ,  Celine Bonnefous ,  Theodore Kamenecka ,  Jean-Michel Vernier ,  John Hutchinson ,  Essa Hu ,  Steven Govek

IPC分类号： A61K31/542 ,  A61K31/538 ,  A61K31/519 ,  C07D498/02 ,  C07D487/02 ,  C07D491/02

CPC分类号： C07D413/08 ,  C07D413/14 ,  C07D417/14

摘要： Cyclopentyl compounds linked to a benzoxazinyl group through an amido moiety utilizing the ring nitrogen of the benzoxazine, and further substituted with a heterocyclic moiety, such compounds represented by formula I: which are used to modulate the CCR-2 chemokine receptor to prevent or treat inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis; and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions.

摘要翻译： 通过使用苯并恶嗪的环氮通过酰胺部分连接到苯并恶嗪基的环戊基化合物，并进一步被杂环部分取代，由式I表示的化合物：